^
TNFRSF8 expression
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
belinostat
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
pralatrexate
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
ALK positive
Peripheral T-cell Lymphoma
crizotinib
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
cyclophosphamide oral + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
bortezomib
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
bendamustine
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
lenalidomide
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Peripheral T-cell Lymphoma
RP6530
Sensitive: B - Late Trials
TNFRSF8 positive
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: B - Late Trials
IL2RA expression
Peripheral T-cell Lymphoma
denileukin diftitox
Sensitive: C1 - Off-label
PD-L1 overexpression
Peripheral T-cell Lymphoma
GB226
Sensitive: C3 – Early Trials
PD-1 overexpression
Peripheral T-cell Lymphoma
nivolumab
Sensitive: C3 – Early Trials
RHOA mutation
Peripheral T-cell Lymphoma
copanlisib
Sensitive: C3 – Early Trials
IDH2 mutation
Peripheral T-cell Lymphoma
copanlisib
Sensitive: C3 – Early Trials
TSC2 mutation
Peripheral T-cell Lymphoma
copanlisib
Sensitive: C3 – Early Trials
TNFRSF8 positive
Peripheral T-cell Lymphoma
BV-ICE
Sensitive: C3 – Early Trials
IL10-H
Peripheral T-cell Lymphoma
CHOP
Resistant: C3 – Early Trials
RPS6 underexpression
Peripheral T-cell Lymphoma
ruxolitinib
Sensitive: C3 – Early Trials
TNFRSF8 negative
Peripheral T-cell Lymphoma
chidamide
Sensitive: C3 – Early Trials
TNFRSF8 expression
Peripheral T-cell Lymphoma
CHEP-BV
Sensitive: C3 – Early Trials
CXCL12 expression
Peripheral T-cell Lymphoma
tipifarnib
Sensitive: C3 – Early Trials
TET2 mutation
Peripheral T-cell Lymphoma
CHOP
Sensitive: C3 – Early Trials
DNMT3A mutation
Peripheral T-cell Lymphoma
CHOP
Resistant: C3 – Early Trials
TNFRSF8 negative
Peripheral T-cell Lymphoma
rituximab + lenalidomide + brentuximab vedotin
Sensitive: C4 – Case Studies
CD20 overexpression
Peripheral T-cell Lymphoma
CVAD
Resistant: C4 – Case Studies
CD20 overexpression
Peripheral T-cell Lymphoma
rituximab
Sensitive: C4 – Case Studies
CD20 overexpression
Peripheral T-cell Lymphoma
CEOP-E
Resistant: C4 – Case Studies
CD20 overexpression
Peripheral T-cell Lymphoma
DICE
Resistant: C4 – Case Studies